Related Experiment Video
Updated: May 1, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
[Hemodialysis to remove anticoagulant dabigatran during emergencies]
Aldo Carrizo1, Sebastián Campbell
1Servicio de Arritmias y Electrofisiología, Clínica Bazterrica, Buenos Aires, Argentina.
Abstract:
Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation. Unlike warfarin, dabigatran has no known antidote. Hemodialysis has been suggested as a method for removing dabigatran and thereby reducing its anticoagulant effect. We report the case of a patient with a known history of atrial fibrillation, treated with dabigatran, who was admitted for emergency abdominal surgery. At six hours after the last dose received, coagulation studies were altered. In absence of an antidote to reverse its effects, it was decided to perform hemodialysis. After three hours of dialysis coagulation parameters were improved and the patient underwent surgery without showing abnormal bleeding during surgery or in the postoperative period.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Venous Thrombosis III: Interprofessional Care
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemodialysis I: Introduction

